Skip to main content
OpenTrials
Completed

NCT Number: NCT02663232

Study to Analyze Mutations in V600 BRAF Oncogen in Participants With Metastatic Melanoma

This is a national, multicenter, cross-sectional epidemiological study in adult Spanish participants diagnosed with advanced or metastatic melanoma.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Palma de Mallorca, Balearic Islands, Spain

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Valid tumor samples from participants diagnosed with Stage IIIc or IV melanoma
  • Written informed consent granted

Exclusion criteria

  • Do not fulfill one or more inclusion criteria

Treatment and study plan

Primary outcomes

  1. Percentage of Participants With V600 BRAF Mutation Status

    Time frame: Day 1

    Presence or absence of mutations in the V600 BRAF oncogene was determined in all eligible participants. Data collection and management of BRAF mutation testing was carried out using the Biomarker point® online platform. The platform was used as an electronic case report form (e-CRF) for collecting information in electronic format via a website. Percentage of participants with BRAF mutation status (mutated BRAF, wild type, not available) were reported.

Secondary outcomes

  1. Percentage of Participants Categorized by Melanoma Stage

    Time frame: Day 1

    Melanoma stages were categorized (according to American Joint Committee on Cancer [AJCC]) as IIIc (advanced stage of melanoma), M1a (metastases to skin, subcutaneous, or distant lymph nodes, normal lactate dehydrogenase (LDH) level, M1b (lung metastases, normal LDH) and M1c (metastases to all other visceral sites and normal LDH or distant metastases to any site combined with an elevated serum LDH level). Of these Stage IIIc was used as the referral category for comparisons.

  2. Percentage of Participants With Family History of Melanoma

    Time frame: Day 1

  3. Percentage of Participants With Sun Exposure

    Time frame: Day 1

    Data were obtained to classify the population with sun exposure as those with low, intermittent or chronic exposure. For the sub-analysis of low, intermittent and chronic exposure, percentages were calculated based on the population with any sun exposure.

  4. Percentage of Participants Categorized by Primary Tumor Location

    Time frame: Day 1

    Primary tumor location included limbs (upper and lower extremities), trunk, head/neck, mucosa, uveal, acral, other (other than these specified locations), unknown (exact location unknown), and not available.

  5. Percentage of Participants Categorized By LDH Level

    Time frame: Day 1

    Normal LDH levels range from 140 units per liter (U/L) to 280 U/L.

  6. Median Time Since Diagnosis of Melanoma

    Time frame: Day 1

    Median time from the diagnosis of primary melanoma to advanced disease was determined in years.

  7. Percentage of Participants Categorized by Tumor Sample Source (Primary Tumor or Metastatic Sites)

    Time frame: Day 1

  8. Percentage of Participants Categorized by Tumor Sample Type (Paraffin-embedded Tissue Blocks, Paraffin Block Slides, Cytology Slides, or Other)

    Time frame: Day 1

  9. Percentage of Participants Categorized by Method of Fixation (Buffered Formalin or Others)

    Time frame: Day 1

  10. Percentage of Participants Categorized by Breslow Thickness

    Time frame: Day 1

    Breslow thickness is defined as the total vertical height of the melanoma, from the very top (called the granular layer) to the area of deepest penetration in the skin. An instrument called an ocular micrometer is used to measure the thickness of the excised (removed) tumor. In general, the higher the Breslow thickness, the worse the prognosis. The classifications were lesser than or equal to (≤) 1.0 millimeters (mm), 1.01 - 2.0 mm, 2.01 - 4.0 mm, greater than (>) 4.0 mm and Unknown.

  11. Percentage of Participants With Ulceration

    Time frame: Day 1

  12. Percentage of Participants With Regression

    Time frame: Day 1

    Regression in melanoma is the replacement of tumor tissue with fibrosis, degenerated melanoma cells, lymphocytic proliferation, and telangiectasia formation.

  13. Percentage of Participants With Vascular Invasion

    Time frame: Day 1

    Vascular invasion is defined as the appearance of cancer cells in the lymphatic and blood streams.

  14. Percentage of Participants Categorized by Method of DNA Extraction (Cobas® BRAF V600 Mutation Test or Others)

    Time frame: Day 1

  15. Percentage of Participants Categorized by Method of BRAF Mutation Testing (Cobas® 4800 BRAF V600 Mutation Test or Others)

    Time frame: Day 1

  16. Percentage Participants Categorized by the Percentage of Tumor Cells Referred to the Technique

    Time frame: Day 1

    The samples were classified based on the percentage of tumor cells referred to the technique as follows: <60 percent (%), 60-80%, >80% and Unknown.

  17. Percentage of Participants With Adequate Quality/Quantity of Tumor Sample

    Time frame: Day 1

Sponsors and collaborators

Lead sponsor

Hoffmann-La Roche

Industry

Registry information

Official study title

Epidemiological Study of V600 BRAF Mutation in Spanish Patients Diagnosed With Metastatic Melanoma: ABSOLUT-BRAF Study

Important dates

Study start
2013
Primary completion
2014
Study completion
2014
First posted
Jan 26, 2016
Registry last updated
Jul 3, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.